Neurogene Inc.
NGNEHeld by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase2 readout: Nov 2028. Short interest: 29.5% of float.
Held by 12 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying12 funds opened new positions. Next phase2 readout: Nov 2028. Short interest: 29.5% of float.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.